Empagliflozin generic name
Pro Research Analysisby 
Searched over 200M research papers
Empagliflozin Generic Name and Its Clinical Implications
Introduction to Empagliflozin (Jardiance®)
Empagliflozin, marketed under the brand name Jardiance®, is a potent and highly selective sodium glucose cotransporter-2 (SGLT2) inhibitor. It is widely approved for the treatment of adults with type 2 diabetes (T2D) in various regions, including the EU, USA, and Japan . This medication is known for its once-daily oral administration and low risk of hypoglycemia due to its insulin-independent mechanism of action .
Pharmacokinetics and Bioequivalence of Generic Empagliflozin
A study aimed at assessing the bioequivalence of a generic empagliflozin tablet compared to the brand-named Jardiance® found that the major pharmacokinetic parameters, including maximum concentration (Cmax) and area under the curve (AUC), were similar between the generic and brand-named tablets under both fasting and fed conditions . The 90% confidence intervals for the test/reference ratios of log-transformed Cmax and AUC values were within the acceptable range, indicating bioequivalence . Additionally, high-fat food did not significantly affect the pharmacokinetics of empagliflozin, and the generic formulation was well tolerated with no serious adverse events reported .
Efficacy and Safety of Empagliflozin in Combination Therapy
Empagliflozin has been evaluated in combination with other antidiabetic agents to enhance glycemic control. In a 52-week, double-blind, randomized, placebo-controlled trial, the efficacy and safety of empagliflozin as an add-on to linagliptin in a fixed-dose combination were assessed in Japanese patients with T2D . The study demonstrated that the combination of empagliflozin and linagliptin significantly improved glycemic control in patients who were insufficiently controlled on linagliptin alone .
Cardioprotective and Renoprotective Benefits
Beyond its glucose-lowering effects, empagliflozin has shown favorable outcomes on several nonglycemic parameters, including modest reductions in body weight and blood pressure . Notably, empagliflozin has demonstrated cardioprotective and renoprotective properties in patients with T2D and established cardiovascular disease (CVD), as evidenced by the EMPA-REG OUTCOME trial . Unlike canagliflozin, another SGLT2 inhibitor, empagliflozin has not been associated with an increased risk of amputation or bone fractures, making it a safer option for long-term use .
Conclusion
Empagliflozin, both in its brand-named form (Jardiance®) and as a generic tablet, is a valuable treatment option for managing type 2 diabetes. Its bioequivalence to the brand-named product ensures similar efficacy and safety profiles, while its combination with other antidiabetic agents like linagliptin offers enhanced glycemic control. Additionally, its cardioprotective and renoprotective benefits make it a preferred choice for patients with high cardiovascular risk.
Sources and full results
Most relevant research papers on this topic